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Inhaled corticosteroids (ICS) are used as anti-inflammatory controller therapy given 1 
either alone or combination with long acting bronchodilators for persistent asthma . 2 
The present COVID-19 pandemic has inevitably focussed attention as to whether ICS 3 
might predispose to SARS-CoV-2 infection , especially in older ,male, obese, 4 
smokers with comorbidities including chronic lung disease who are prone to more 5 
severe COVID-19 infection and worse outcomes. In the later stage of COVID-19 6 
infection there is an acute inflammatory cytokine cascade including interleukin 1-beta 7 
(IL1-β) , interleukin-6 (IL6) and tumour necrosis factor  alpha (TNF-α). This in turn 8 
results in a hyper-inflammatory and coagulopathy state with acute respiratory distress 9 
syndrome and an attendant high morality rate. A United Kingdom database of 17 10 
million adult patients reported the .presence of asthma without recent oral 11 
corticosteroid use was associated with a 10% increased risk of hospital death with 12 
COVID-19 , which doubled to 20% in those with recent oral corticosteroid (OCS) 13 
use. The present evidence does not support the use of systemic corticosteroids for 14 
treating COVID-19. .Although ICS exhibit dose related systemic absorption from the 15 
lung the degree of attendant systemic glucocorticoid activity in asthma is relatively 16 
low compared to OCS. Whether or not ICS might confer a different  risk-benefit 17 
profile in COVID-19 is presently unknown . Here we discuss the pros and cons of 18 
using ICS in relation to COVID-19 (Figure ) .  19 
Concerns around the use of ICS in asthma in COVID-19 arise from the potential 20 
immunosuppressive effects in the lungs especially in the presence of impaired host 21 
defence. The premise here is that corticosteroids  may promote viral replication, 22 
delayed viral clearance and also predispose to secondary bacterial infection. In 23 
support of this a Canadian cohort study of asthma patients demonstrated that current 24 
exposure to ICS was accompanied by a 45% relative increase in bacterial pneumonia 25 
 2
risk . In contrast a study in H1N1 influenza A infection among 1520 UK hospitalized 26 
patients found those with asthma were 49% less likely to require intensive care 27 
support or to die than those without asthma , which was attributed to ICS use.  28 
This in turn suggests the possibility of a class effect of ICS by protecting against viral 29 
insults in asthma patients, which might be due to downstream cytokine suppression . 30 
In favour  of this hypothesis in vitro suppressive effects were seen with budesonide on 31 
replication of coronavirus HCoV-229E (the common cold) and on production of 32 
cytokines including IL6 ,IL8 and interferon-β ,using primary cultures of human nasal 33 
and tracheal epithelial cells ,while another in vitro study showed systemic suppression 34 
of IL6 by budesonide1, 2. This could be particularly relevant as raised levels of IL6 are 35 
strongly related to worse outcomes in patients with severe COVID-19 pneumonia 36 
with evidence of hyper-inflammation. In addition it has been shown that in sputum 37 
cells from 330 asthma patients the use of ICS was associated with reduced gene 38 
expression of angiotensin converting enzyme 2 (ACE2) and transmembrane serine 39 
protease 2 (TMPRSS2) , both of which are pivotal membrane bound receptors 40 
involved in host cell entry of severe acute respiratory syndrome coronavirus 2 41 
(SARS-CoV-2) 3. Moreover in patients with type 2  asthma exposure to exogenous  42 
interleukin-13  in ex vivo primary airway epithelial cells decreases ACE2 and 43 
increases TMPRSS2 expression 4. Whether altered cell receptor expression might 44 
translate into reduced viral load with ICS therapy is unknown . 45 
There are also preliminary data to perhaps suggest a more specific salutary effect of 46 
ICS with COVID-19 . In vitro experiments have shown that ICS may not all be same 47 
in that low concentrations of  ciclesonide and mometasone but not fluticasone 48 
,budesonide or beclomethasone appear to suppress replication of SARS-CoV-2 , to 49 
the same degree as lopinavir .5 The inhibitory action  of ciclesonide on replication of 50 
 3
SARS-CoV-2 was mediated via non-structural protein 15 (NSP15) . There have been 51 
case reports of COVID-19 pneumonia successfully treated with inhaled ciclesonide 52 
but no data yet from ongoing randomised controlled trials (NCT04416399, 53 
NCT04381364, NCT04377711). In respect of COVID pneumonia inhaled ciclesonide 54 
achieves high alveolar deposition and prolonged lung retention due to formation of 55 
intracellular fatty acid conjugates, in addition to producing minimal systemic adverse 56 
effects at higher doses  .  57 
As an initial step health informatics studies may help to elucidate if ICS might 58 
alleviate or worsen COVID-19 outcomes in asthma patients, in particular looking at 59 
dose response effects . Randomized controlled trials may also be warranted in patients 60 
who do not have asthma perhaps to see if secondary prevention with ICS including 61 
ciclesonide or mometasone can prevent progression of early COVID infection in 62 
susceptible older patients with comorbidities . Meanwhile for patients with asthma the 63 
current guidance is to continue taking their ICS containing controller therapy because 64 
ultimately this may also confer optimal  protection against viral infections including 65 
SARS-CoV-2 and also prevent eosinophilic related exacerbations . 66 
Figure Legend  67 
 68 
Depicts putative positive and negative effects of inhaled corticosteroids in COVID-19 69 
infection on (a) viral replication of severe acute respiratory syndrome coronavirus 2 70 
(SARS-CoV-2) including specific effects of mometasone furoate and ciclesonide on 71 
non structural protein 15 (NSP15), (b) reduced expression of angiotensin converting 72 
enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) , (c) suppression 73 
of pro-inflammatory cytokines including interleukin-6 (IL6) , (d) promotion of 74 
 4
secondary bacterial infection , (e) effects on neutrophils and eosinophils , (f) 75 
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